Table 2 Comparison of clinicopathological factors between the asymptomatic and symptomatic groups according to subtype.
Luminal | HER2 | Triple negative | ||||
|---|---|---|---|---|---|---|
Asymptomatic MBC (n = 75) | Symptomatic MBC (n = 45) | Asymptomatic MBC (n = 27) | Symptomatic MBC (n = 23) | Asymptomatic MBC (n = 12) | Symptomatic MBC (n = 22) | |
Agea, years | 62 (36–88) | 59 (26–91) | 56 (36–77) | 56 (31–82) | 56 (41–81) | 59 (26–88) |
Recurrence-free survival, months | 46 (13–237) | 54 (5–309) | 54.5 (7–182) | 54.5 (13–210) | 20 (4–108) | 22 (4–71) |
Visceral metastasisa | 49 (65.3%) | 23 (51.1%) | 16 (59.3%) | 15 (65.2%) | 5 (41.7%) | 10 (45.5%) |
Multiple metastatic sitesa | 28 (37.3%) ⁋ | 25 (55.6%) ⁋ | 8 (29.6%) ⁋ | 13 (56.5%) ⁋ | 4 (33.3%) | 10 (45.5%) |
Metastasis siteb | ||||||
Lung | 33 | 15 | 9 | 8 | 4 | 6 |
Bone | 29 | 20 | 9 | 7 | 2 | 9 |
Lymph node | 20 | 19 | 7 | 7 | 6 | 10 |
Liver | 22† | 6† | 8 | 7 | 2 | 2 |
Chest wall | 0† | 5† | 2 | 6 | 1 | 6 |
Brain | 3 | 5 | 1 | 1 | 0 | 1 |
Stage 0/1/2/3/Unknown | 0/14/30/28/3 | 0/4/28/12/1 | 1/6/8/11/1 | 0/4/7/9/2 | 0/2/6/4 | 0/4/13/5 |
